Semaglutide dosage for alcohol cravings in Canada is not officially established, but early studies use 0.25 mg to 1.0 mg weekly, the same range used for diabetes and weight loss. Canadian researchers and clinicians are exploring whether this GLP-1 receptor agonist can reduce alcohol intake. The evidence is promising but still preliminary.
Semaglutide alcohol use disorder research is growing fast. A 2023 case series in the Journal of Clinical Psychiatry reported that six patients with alcohol use disorder (AUD) who took semaglutide for weight loss experienced a significant drop in alcohol cravings. All six reduced their drinking, and most reported less desire to drink. This mirrors findings from animal studies and a growing number of human reports.
If you are in Canada and considering semaglutide for alcohol cravings, you need to know what the studies actually show. This article breaks down the dosage, the evidence, and what to expect. We also cover how to access semaglutide in Canada, including research peptide options.
What is semaglutide and how does it affect alcohol cravings?
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes. It mimics the hormone GLP-1, which regulates blood sugar and appetite. But GLP-1 receptors are also found in brain areas linked to reward and addiction. That is why semaglutide may reduce alcohol cravings.
In animal studies, semaglutide reduced alcohol intake in rodents bred to drink heavily. It also reduced relapse-like drinking after a period of abstinence. The mechanism likely involves dampening the dopamine reward signal from alcohol. This makes drinking less pleasurable and reduces the urge to drink.
Human data is still limited but growing. A 2024 observational study of 48 people with AUD found that those taking semaglutide or tirzepatide drank significantly less than those not on the medication. The effect was strongest for those with higher baseline drinking. Another small trial is underway at the University of North Carolina, testing semaglutide specifically for alcohol use disorder.
Semaglutide dosage for alcohol cravings: what the studies use
No official semaglutide dosage exists for alcohol cravings. But the studies and case reports use the same titration schedule as for diabetes or obesity. The typical starting dose is 0.25 mg injected subcutaneously once weekly for four weeks. Then the dose increases every four weeks: 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg if tolerated.
In the 2023 case series, patients were on doses ranging from 0.5 mg to 2.4 mg weekly. Most saw a reduction in cravings at the lower end of that range. Some needed the full 2.4 mg dose. The key is to titrate slowly to minimize nausea and other GI side effects.
For research purposes in Canada, semaglutide is available as a lyophilized powder for reconstitution. If you are buying semaglutide for research, you will need to know how to reconstitute it properly. Our guide on reconstituting semaglutide 5mg for research walks you through the steps. Always use sterile bacteriostatic water and follow proper lab protocols.
GLP-1 alcohol cravings study: key findings
The most cited GLP-1 alcohol cravings study is a 2023 randomized controlled trial published in JAMA Psychiatry. It tested exenatide, a shorter-acting GLP-1 agonist, in 127 people with AUD. The exenatide group did not reduce heavy drinking days overall. But a subgroup with obesity showed a significant reduction. This suggests GLP-1 drugs may work better in people with higher body weight or metabolic issues.
Semaglutide is more potent and longer-acting than exenatide. That may make it more effective for alcohol cravings. A 2024 preprint from the University of Copenhagen reported that semaglutide reduced alcohol intake by 30% in a small human laboratory study. Participants also reported less craving after being exposed to alcohol cues.
Another ongoing trial, STAR (Semaglutide for Alcohol Use Disorder), is testing 2.4 mg weekly against placebo. Results are expected in 2025. If positive, it could lead to a new indication for semaglutide in Canada and elsewhere.
Semaglutide alcohol use disorder: what Canadian patients should know
In Canada, semaglutide is approved for type 2 diabetes (as Ozempic) and for weight loss (as Wegovy). It is not approved for alcohol use disorder. That means any use for alcohol cravings is off-label. Doctors can prescribe it off-label, but coverage is unlikely. Most private insurers will not pay for off-label use.
Some Canadians are turning to research peptide suppliers for semaglutide. This is a gray area. Research peptides are sold for laboratory use only, not for human consumption. But many people buy them for personal use. If you go this route, you must understand the risks: no quality control, no dosing guidance, and potential legal issues.
For those in Quebec or other provinces, the process is similar to buying other research peptides. You can find semaglutide from online vendors that ship within Canada. Always verify the supplier's reputation and ask for third-party testing. If you are new to research peptides, read our guide on reconstituting research peptides safely to avoid common mistakes.
Dosing schedule and titration for alcohol cravings
If you are using semaglutide for alcohol cravings in a research or off-label setting, follow the standard titration. Start at 0.25 mg once weekly for four weeks. This low dose helps your body adjust and reduces nausea. Then increase to 0.5 mg for four weeks. After that, you can go to 1.0 mg if needed.
Most case reports show a reduction in alcohol cravings at 0.5 mg to 1.0 mg weekly. Some people need 1.7 mg or 2.4 mg. Do not jump to a high dose quickly. That increases the risk of severe GI side effects like vomiting and pancreatitis.
Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites. The half-life of semaglutide is about one week, so weekly dosing keeps blood levels steady. If you miss a dose, take it as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and take the next one on schedule.
Side effects and safety considerations
Semaglutide is generally well tolerated, but GI side effects are common. Nausea, vomiting, diarrhea, and constipation affect up to 20% of users. These usually improve after a few weeks. Starting low and titrating slowly reduces the risk.
More serious side effects are rare but possible. Pancreatitis, gallbladder disease, and kidney injury have been reported. Semaglutide also carries a boxed warning for thyroid C-cell tumors in rodents. It is not known if this risk applies to humans. Do not use semaglutide if you have a personal or family history of medullary thyroid carcinoma or MEN2.
For alcohol use disorder, combining semaglutide with other treatments may be beneficial. Naltrexone, acamprosate, and counseling are standard. Semaglutide could be an add-on. But no studies have tested this combination. Talk to a doctor before mixing medications.
Where to buy semaglutide for research in Canada
If you are a researcher in Canada looking to buy semaglutide for alcohol craving studies, you have options. Several Canadian peptide suppliers offer semaglutide in 5mg vials. Prices range from $80 to $150 CAD per vial. That is significantly cheaper than brand-name Ozempic or Wegovy, which cost $200 to $400 per month without insurance.
When buying research semaglutide, look for a supplier that provides a certificate of analysis (COA) from an independent lab. This verifies purity and concentration. Avoid vendors that do not offer testing or that have poor reviews. For a detailed guide on sourcing semaglutide in Canada, check our article on reconstituting semaglutide 5mg for weight loss, which also covers supplier vetting.
Remember that research peptides are not for human use. If you choose to use them personally, you accept all risks. Always consult a healthcare provider before starting any new treatment.
Semaglutide vs other GLP-1 agonists for alcohol cravings
Semaglutide is not the only GLP-1 drug being studied for alcohol use disorder. Liraglutide, dulaglutide, and tirzepatide have also shown promise. Tirzepatide is a dual GIP/GLP-1 agonist and may be even more effective for weight loss and possibly alcohol cravings. But it is newer and less studied for AUD.
Semaglutide has the advantage of once-weekly dosing and a long track record. It also has the most human case reports for alcohol cravings. If you are considering a GLP-1 for this purpose, semaglutide is the most logical first choice. But tirzepatide is worth watching as more data emerges.
For a comparison of semaglutide with other research peptides for different goals, see our article on BPC-157 vs TB-500 for tissue repair. While not directly related to alcohol cravings, it shows how different peptides target different pathways.
What the future holds for semaglutide and alcohol use disorder
The evidence for semaglutide in alcohol use disorder is growing. Several clinical trials are underway. If they show a clear benefit, semaglutide could become a new tool for treating AUD. That would be a major advance, as current medications have limited efficacy.
In Canada, Health Canada would need to approve a new indication. That process takes time. But off-label use is already happening. Some addiction specialists are prescribing semaglutide to patients with both obesity and AUD. The results are anecdotal but encouraging.
For now, the best approach is to stay informed. Follow the published studies. If you are a researcher, consider adding semaglutide to your protocols. And